- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07949682
Peripheral Perfusion After UNIFUZOL® Versus Lactated Ringer's in Resolving Septic Shock (UNIRING-OBS SH)
Prospective Multicenter Observational Comparative Cohort Study of Actual UNIFUZOL® (Arginine Sodium Succinate) Versus Lactated Ringer's Use in Adults With Urinary- or Pulmonary-Source Sepsis During the Early Stabilization/Resolving Phase of Septic Shock and Documented Lower-Extremity Atherosclerotic Disease: Peripheral Perfusion, NIRS Vascular Reactivity, and Macro-Microhemodynamic Coherence
Peripheral Perfusion After UNIFUZOL® Versus Lactated Ringer's in Resolving Septic Shock
Studienübersicht
Status
Studientyp
Einschreibung (Geschätzt)
Kontakte und Standorte
Studienkontakt
- Name: Alexey Kovalenko, Doc Biol Sci
- Telefonnummer: 212 +78127108225
- E-Mail: science@polysan.ru
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Adults treated in participating intensive care units for urinary- or pulmonary/respiratory-source sepsis with current or recently documented septic shock, documented lower-extremity atherosclerotic peripheral artery disease, early hemodynamic stabilization, ongoing hypoperfusion, and PiCCO Plus already in place for clinical indications. Potentially eligible participants are screened consecutively during active recruitment periods.
Beschreibung
Inclusion Criteria:
- Age 18 years or older.
- Septic shock by Sepsis-3 currently or documented within the previous 24 hours.
- Urinary or pulmonary/respiratory suspected or confirmed infection source.
- Documented atherosclerotic disease of the lower-extremity arteries.
- Mean arterial pressure at least 65 mm Hg with norepinephrine less than 0.2 micrograms/kg/min and no increase greater than 20 percent or new vasopressor during the previous 30 minutes.
- PiCCO Plus already installed for clinical indications and technically usable.
- At least one ongoing sign of hypoperfusion or microcirculatory dysfunction defined in the protocol.
- Before any study-specific baseline procedure, the treating physician has independently decided that an additional crystalloid infusion is clinically indicated and has selected UNIFUZOL® or lactated Ringer's solution.
- Thenar NIRS-VOT can be performed safely.
- Informed consent or another ethics-board-approved consent process is completed before study-specific procedures.
Exclusion Criteria:
- Hemorrhagic, cardiogenic, or obstructive shock as the leading cause of instability.
- Rapidly increasing vasopressor requirement or need for immediate hemodynamic rescue inconsistent with the protocol-defined stabilization phase.
- Clinically important fluid overload/pulmonary edema for which the treating physician considers additional fluid contraindicated; severe unstable ARDS.
- Active major bleeding or another condition requiring urgent therapy that prevents standardized baseline assessment.
- Expected survival less than 24 hours or limitation of intensive treatment.
- Pregnancy or breastfeeding.
- Participation in an interventional study expected to materially affect hemodynamics.
- Contraindication to any component of the physician-selected fluid.
- Upper-limb ischemia, severe Raynaud phenomenon, local thenar skin injury, or another condition making NIRS-VOT unsafe or uninterpretable.
- Core temperature below 34 degrees Celsius.
- Acute/critical lower-extremity ischemia requiring urgent vascular treatment or severely compromising peripheral assessments.
- Unable to establish Tdecision/T0 or obtain pre-infusion baseline CRT; inability to obtain pre-infusion ReOx excludes the participant from the key NIRS analysis.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: CASE_CONTROL
- Zeitperspektiven: PROSPECTIVE
Kohorten und Interventionen
Gruppe / Kohorte |
|---|
|
UNIFUZOL® exposure cohort
Participants for whom the treating physician independently selected and actually started UNIFUZOL® at T0. The protocol does not determine indication, dose, rate, duration, repeat administration, or subsequent fluids. |
|
Lactated Ringer's exposure cohort
Participants for whom the treating physician independently selected and actually started lactated Ringer's solution at T0. The protocol does not determine indication, dose, rate, duration, repeat administration, or subsequent fluids. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Capillary Refill Time at 6 Hours
Zeitfenster: 6 hours after start (window ±60 minutes)
|
Capillary refill time (CRT) in seconds measured using a standardized distal-finger technique. Two valid measurements are averaged; if they differ by more than 1.0 second, a third measurement is obtained and the median of three is used. The primary statistical comparison adjusts for strictly pre-infusion CRT and prespecified baseline covariates. Lower CRT is considered physiologically favorable. |
6 hours after start (window ±60 minutes)
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Thenar NIRS Reoxygenation Slope at 6 Hours
Zeitfenster: 6 hours after start (window ±60 minutes)
|
Post-occlusion reoxygenation slope (ReOx) derived from a standardized thenar near-infrared spectroscopy vascular occlusion test using a frozen common device/software/analysis algorithm. ReOx is analyzed continuously in percent StO2 per second and adjusted for pre-infusion ReOx. Higher ReOx is considered physiologically favorable. |
6 hours after start (window ±60 minutes)
|
|
Sustained Macro-Microhemodynamic Coherent Response
Zeitfenster: 6 and 12 hours after start
|
Protocol-defined supportive composite outcome. This measure is reported as a single binary value (Yes/No), which is considered achieved only if ALL of the following criteria are simultaneously met: full macrohemodynamic stability, peripheral/microvascular recovery, and pulmonary/volume safety at both 6 and 12 hours. The composite is not a validated diagnostic criterion and is analyzed as supportive/exploratory. |
6 and 12 hours after start
|
|
Change in Capillary Refill Time Over 24 Hours
Zeitfenster: From start through 24 hours
|
Serial CRT at 60 minutes, approximately 2 hours/end of infusion, 6 hours, 12 hours, and 24 hours; analyses include continuous change and trajectory models. |
From start through 24 hours
|
|
Change in ReOx
Zeitfenster: From pre-infusion baseline through 24 hours
|
Serial ReOx from standardized NIRS-VOT. |
From pre-infusion baseline through 24 hours
|
|
Change in De-oxygenation slope
Zeitfenster: From pre-infusion baseline through 24 hours
|
DeOx from standardized NIRS-VOT (%/min). |
From pre-infusion baseline through 24 hours
|
|
Change in NIRS Vascular Reactivity Over 24 Hours (tissue oxygenation)
Zeitfenster: From pre-infusion baseline through 24 hours
|
Tissue oxygenation variables (%) |
From pre-infusion baseline through 24 hours
|
Mitarbeiter und Ermittler
Ermittler
- Studienstuhl: K.M. Lebedinsky, North-Western State Medical University named after I.I.Mechnikov
- Hauptermittler: I. S. Simutis, Adult Intensive Care Unit, L.G. Sokolov North-Western District Scientific and Clinical Center, FMBA of Russia, St Petersburg, Russian Federation
- Hauptermittler: A.Yu. Yakovlev, City Hospital No. 38 named after N.A. Semashko
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Gefäßerkrankungen
- Herz-Kreislauf-Erkrankungen
- Pathologische Prozesse
- Infektionen
- Systemisches Entzündungsreaktionssyndrom
- Entzündung
- Atherosklerose
- Arteriosklerose
- Arterielle Verschlusskrankheiten
- Periphere Gefäßerkrankungen
- Schock
- Pathologische Zustände, Anzeichen und Symptome
- Sepsis
- Periphere arterielle Verschlusskrankheit
- Schock, Septisch
Andere Studien-ID-Nummern
- UNIRING-OBS SHOCK
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .